But GLP-1 Medications are not a miracle drug
"That lack of clinical oversight is dangerous for patient safety
It matters for coverage, cost, and the approved indication
Energy isn't the only potential bottleneck
At Salish Shore Wellness , we understand that weight loss isnt just about willpowerits about science, support, and solutions that work
I built this matrix by mapping each row to the single trial endpoint that produced the highest-quality primary evidence as of mid-2026: percent body-weight change for efficacy (Jastreboff 2023, SURMOUNT-1, STEP 1), three-point MACE for cardiovascular (SELECT), MRI-PDFF for hepatic fat (retatrutide Phase 2 sub-analyses, [unverified primary source]), and treatment-emergent adverse event rates for GI burden